ChemPartner PharmaTech Co., Ltd. Class A

ChemPartner PharmaTech Co., Ltd. Class A

SSZSE:300149
8.08
CNY
-0.18
(-2.18%)
-0.01EPS
5.00BMarket Cap

Total Valuation

CNY

As of September 30, 2026, ChemPartner PharmaTech Co., Ltd. Class A carries a market capitalization of 5.00B, placing it among publicly traded companies globally. Its enterprise value stands at 5.08B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap5.00B
Enterprise Value5.08B

Share Statistics

As of September 30, 2026, ChemPartner PharmaTech Co., Ltd. Class A has 504.99M shares outstanding.

Shares Outstanding504.99M

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 3.82, and the price-to-book ratio stands at 3.76.

PS Ratio3.82
PB Ratio3.76
P/TBV Ratio3.86

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 4.01 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 5.08B versus a market cap of 5.00B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales4.01

Financial Position

As of September 30, 2026, ChemPartner PharmaTech Co., Ltd. Class A maintains a current ratio of 1.99, meaning it holds 2.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 35.91, indicating elevated leverage, while an interest coverage ratio of -0.07 demonstrates limited ability to service its debt obligations.

Current Ratio1.99
Quick Ratio1.02
Debt / Equity35.91
Debt / EBITDA-409.89
Interest Coverage-0.07

Financial Efficiency

CNY

These figures cover the twelve months ended September 30, 2026. The company generates approximately 714,379.76 in revenue per employee across its workforce of 1,771.00, a quick read on workforce productivity versus industry peers.

Revenue Per Employee714,379.76
Employee Count1,771.00

Taxes

CNY

Over the twelve months ended September 30, 2026, ChemPartner PharmaTech Co., Ltd. Class A recorded an income tax benefit of -3.98M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -10.88M and -7.00M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax-3.98M

Stock Price Statistics

CNY

As of the close on November 17, 2026, ChemPartner PharmaTech Co., Ltd. Class A's stock has declined approximately 28.18% over the past 52 weeks. The 50-day moving average sits at 8.81, while the 200-day moving average is 9.65.

52-Week Price Change-28.18%
50-Day Moving Average8.81
200-Day Moving Average9.65

Income Statement

CNY

Over the twelve months ended September 30, 2026, ChemPartner PharmaTech Co., Ltd. Class A generated 1.27B in revenue and converted that into -7.00M in net income, yielding earnings per share of -0.01. EBITDA reached -1.19M, while operating income came in at 48.09M.

Revenue1.27B
Gross Profit345.04M
Operating Income48.09M
Pretax Income-10.88M
Net Income-7.00M
EBITDA-1.19M
EBIT-1.19M
Earnings Per Share (EPS)-0.01

Balance Sheet

CNY

As of September 30, 2026, ChemPartner PharmaTech Co., Ltd. Class A holds 440.17M in cash and equivalents against 488.04M in total debt, resulting in a net debt position of -309.04M. Total book value stands at 1.33B, with working capital of 427.34M providing operational flexibility.

Cash & Cash Equivalents440.17M
Total Debt488.04M
Net Debt-309.04M
Equity (Book Value)1.33B
Book Value Per Share2.63
Working Capital427.34M

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-87.22M

Margins

Over the twelve months ended September 30, 2026, ChemPartner PharmaTech Co., Ltd. Class A posted a gross margin of 27.27, reflecting its pricing power and cost economics. The operating margin of 3.80 and net profit margin of -0.55 provide insight into operational efficiency.

Gross Margin27.27
Operating Margin3.80
Pretax Margin-0.86
Profit Margin-0.55
EBITDA Margin-0.09

Dividends & Yields

Over the twelve months ended September 30, 2026, ChemPartner PharmaTech Co., Ltd. Class A paid dividends of 0.00 per share. The dividend payout ratio of -32.99 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 0.43, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to ChemPartner PharmaTech Co., Ltd. Class A shareholders.

Payout Ratio-32.99
Shareholder Yield0.43

Stock Splits

ChemPartner PharmaTech Co., Ltd. Class A's most recent stock split took place on May 21, 2015 with a 5:7 split ratio.

Last Split Date5/21/2015
Split Ratio5:7

Scores

As of September 30, 2026, ChemPartner PharmaTech Co., Ltd. Class A has an Altman Z-Score of 4.26, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score4.26